Scandion Oncology: Our Q4 comment - Redeye

Redeye comments on Scandion’s fourth quarter report for 2021, going into an important year for the company. Scandion faces two essential clinical readouts with CORIST phase II part 2 and PANTAX phase Ib top-line data scheduled for release in Q2 to Q3 2022. These readouts are well within the company’s communicated funding runway into 2023, leaving room to evaluate and start executing strategic options following top-line data release.

Länk till analysen i sin helhet: https://www.redeye.se/research/833432/scandion-oncology-our-q4-comment?utm_source=finwire&utm_medium=RSS